PRX belongs to a new class of anti-folates designed to have improved affinity for the
reduced folate carrier. A phase 2 study at 135 mg/m2 given on an every other week (w) …

T-cell lymphomas (TCL) represent a diverse and heterogeneous group of diseases. The
prognosis of patients with TCL is generally much worse than for patients with B-cell …

8054 Background: Pralatrexate (FOLOTYN) is a targeted antifolate designed for preferential
uptake and accumulation in tumor cells, due to high affinity for reduced folate carrier and …

C85 Pralatrexate is a novel folate analogue designed to have high affinity for the reduced
folate carrier (RFC-1), exhibiting improved internalization and efficacy over other …

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity
Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma …

T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief
durations of remissions. An early phase study of pralatrexate has demonstrated dramatic …

Purpose: The pharmacology, pharmacokinetics, clinical trials, adverse effects, dosage, and
economic considerations of pralatrexate (PDX) are reviewed. Summary: Peripheral T-cell …

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or
refractory peripheral T‐cell lymphoma. To assess its safety, efficacy, and pharmacokinetics …

Abstract Abstract 1675 Poster Board I-701 Background Chemotherapeutic agents may be
associated with early-onset toxicities (eg, bortezomib peripheral neuropathy) or late …

Pralatrexate is an antifolate designed to be internalized more rapidly than other traditional
antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early …